Impact of Mobile Health Technology Application on Proximal Humerus Fracture Care Practice and Patient Self-Care Outcomes - A Pilot Randomized Controlled Trial
Impact of Mobile Health Technology Application on Proximal Humerus Fracture Care Practice and Patient Self-Care Outcomes - A Pilot Randomized Controlled Trial
Proximal humerus fracture patient's upper limb complete function restoration mainly depends on patient rehabilitation exercises. One time teaching in clinic is usually not sufficient for patients to learn their rehabilitation exercises. This leads to delayed patient recovery and dis-satisfaction to treatment provided by health care providers.
Our aim is that mobile health technology might facilitate patient to easily access health related teaching information other than routine care to support patient in their self-health care management thus leading to proximal humerus fracture patient treatment outcome improvement.
Hypothesis:
Mobile health technology positively improves clinical and functional outcomes of proximal humerus fracture using validated outcome scoring scales.
Objectives:
Primary objective:
Secondary Objective: To increase patient and doctor satisfaction rate in perspective with treatment provision usefully by digital technology application.
Methods:
Study design: Patient-centered, open labelled, parallel (1:1), pilot randomized controlled trial.
Total 60 subjects required with 30 in each arm in 24-month duration.
Study procedures:
Proximal humerus rehabilitation exercises video will be prepared after obtaining written informed consent from designated orthopaedic residents/surgeon.
Patients of 18 to 58 years of age with trauma associated proximal humerus fractures, who or their attendants are willing to participate. Patients who requires special care, patient not willing to exercise at home without physiotherapist support or participate in survey questionnaire and patients who does not have facility of classic blue tooth connectivity will be excluded.
Written informed consent will be administered the study subjects as per GCP guideline.
Each eligible patient will be randomized into intervention or control group.
The patient will be followed at 6 weeks, 3 and 6 months. Data will be collected on Case report form by assigned person. Clinical and functional outcomes will be assessed by assigned person using Quick DASH and Oxford shoulder score.
Researchers will be trained on data collection form prior to data collection. In case of lost to follow-up, patients will be contacted by telephone.
Patient satisfaction questionnaire: Administered to intervention group only about impact of digital technology application on their health improvement and care outcomes.
Doctor satisfaction questionnaire: To assess treating surgeon satisfaction rate for digital technology application impact on intervention group patients' care and outcomes.
The research study does not seem to have any potential health hazard. As per Food and Drug Administration and GCP recommendations for Serious/Adverse event (SAE/AE), any patient who experience SAE/AE, will receive good clinical care at earliest and all relevant reporting bodies will be notified.
Data management will be carried out at the Department of Surgery. Subject data confidentiality will be maintained. After study completion, data will be archived and retained for maximum years.
Statistical Consideration:
Quantitative variables will be expressed as mean ± standard deviation and qualitative variables as frequencies (percentages). The efficacy on the basis of clinical and functional outcome and the AEs/SAEs will be assessed by intention to treat analysis. For group comparisons of clinical and functional categorical outcomes, chi-square test or Fisher Exact will be applied. p-values of less than 0.05 will be considered as statistically significant with a confidence interval of 95%.
Patient and doctor satisfaction scores will be analyzed using regression analysis. For Assessment of outcomes, repeated measure ANOVA and generalized estimating equation will be used. Multiple regression will be used to assess the association between multiple covariates.
Due to complex anatomy with delayed recovery of proximal humerus fracture patients, there is high need of optimal treatment planning and care delivery process improvement to achieve better treatment outcomes. For current study, musculoskeletal service line at AKU will implement mobile health application specifically for proximal humerus trauma associated fracture patients which is simple to use. Internationally physiotherapy specialty related specific exercises are applied which is bit different from current study in the context of specialty and application. Mostly their focus is on rehabilitation of cases like scoliosis, dementia etc. This is the first time that orthopaedic specialty related, trauma associated, proximal humerus fracture specific modules will be developed with no advance IT based software application due to limited resources and to adhere to the patient data confidentiality. The application will be simple and user-friendly.
For current pilot trial research question is whether mobile health app. improve proximal humerus fracture patient treatment outcomes compared to standard care? Adhering to patient data confidentiality, our aim is that mobile health technology might facilitate patient to easily access health related teaching information other than routine care to support patient in their self-health care management thus leading to proximal humerus fracture patient treatment outcome improvement.
As proximal humerus fracture patient upper limb complete function restoration mainly depends on patient rehabilitation exercises, one time teaching in clinic by surgeons or physiotherapist is usually not sufficient for patients to learn their home rehabilitation exercises in routine practice. This leads to delayed patient recovery and dis-satisfaction to treatment provided by health care providers. Besides standard care, administering teaching video teaching modules with the help of mobile technology specifically for proximal humerus fracture patients might improve patient complete function restoration. Thus, mobile health strategy possibly will assist orthopaedic clinical team to reduce patient visit time, improve patient clinical and functional outcomes with increase in patient satisfaction and quick recovery.
Hypothesis:
Mobile health technology positively improves clinical and functional outcomes of proximal humerus fracture using validated outcome scoring scales.
Objectives:
Primary objective:
Secondary Objective: To increase patient and doctor satisfaction rate in perspective with treatment provision usefully by digital technology application and health information sharing in health care settings.
Methods:
Number of participants:
The minimum sample size that investigator will require is 60 with 30 in intervention arm and 30 in control arm.
Study design: Patient-centered, open labelled, parallel (1:1), pilot randomized controlled trial. (Intervention group receive proximal humerus fracture care with mobile health shared rehabilitation teaching video instructions and control group will receive routine care for proximal humerus fracture as recommended by the treating surgeons).
Study Duration: 24 months
Study procedures: Study procedures will comply with all necessary ethical, Institutional and legal requirements.
In first step of the study, written informed consent will be obtained from designated orthopaedic residents/surgeon prior to video production. Proximal humerus rehabilitation exercises video will be prepared by orthopaedic resident or surgeon under observation of participating surgeon's expertise in which step wise rehabilitation exercises will be demonstrated exclusively for patient's teaching.
Patient eligibility criteria: Patients of 18 to 58 years of age with trauma associated proximal humerus fractures, presented at Orthopaedic inpatient and outpatient units, AKU who or their attendants are willing to follow the rehabilitation instructions via mobile application at home until completion of study follow up visits and agree to participate in very small survey questionnaire in the end of study will be selected. Patients who in special circumstances requiring special care and handling by expert health care providers, patient not willing to exercise at home without physiotherapist support or participate in survey questionnaire and patients who does not have facility of classic blue tooth connectivity for video download will be excluded.
Written informed consent will be administered by designated person as per good clinical practice guideline and obtained from the study subjects within the time of initial hospital arrival to follow-up within 21days post procedure.
Randomization: After obtaining written informed consent, on the same day, each eligible patient will be randomized into intervention or control group by randomly generated treatment allocation, sealed envelope technique will be used.
Patient follow-ups and Data Collection: Patients will be followed at subsequent visits after treatment. The patient will be followed at 6±1 weeks, 3 months ±2 weeks and 6±1 months. Data will be collected on Case report form by assigned person. Clinical and functional outcomes will be assessed by assigned person using Quick DASH and Oxford shoulder score.
In order to reduce bias, researchers will be trained on data collection form prior to data collection. In case of lost to follow-up, patients will be contacted by telephone to gather necessary information.
Patient satisfaction questionnaire: At last follow-up, a small questionnaire by research team will be administered by assigned person to intervention group only about impact of digital technology application on their health improvement and care outcomes.
Doctor satisfaction questionnaire: A small questionnaire by research team will be administered to assess treating surgeon satisfaction rate for digital technology application impact on intervention group patients' care and outcomes.
The research study does not seem to have any potential health hazard. Complying with all regulatory standards and as per International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines, study subjects will be provided optimum care at earliest.
As per Food and Drug Administration (FDA) and GCP definitions and recommendations for Serious/Adverse event (SAE/AE), any patient who experience SAE/AE, will receive good clinical care at earliest and all relevant reporting bodies will be notified. Designated research team member will be responsible to notify the SAE and AE timely to the Principal Investigator and prepare report with complete event details. Principal Investigator is responsible for sending reports to the reporting bodies (Ethical Review Committee, Sponsor etc.) as required, reviewing reports of adverse events (AEs) and serious adverse events (SAEs) that are submitted by designated research team member, identify safety concerns quickly and address in the report appropriately
Study Close-out: Study close-out process will be of two-month duration. Study progress report and all study closing steps will be carried out during this time with manuscript writing and study report submission.
Sampling Method: Non-probability, consecutive sampling
Data management Data management, randomization and the statistical analysis will be carried out at the Department of Surgery. Data entry will be conducted electronically and analyzed on SPSS version 19.0. Fifteen percent of the data will be double checked/validated by the Principal Investigator. Subject data confidentiality will be maintained by assigning subject ID, data entry by assigned person only on password protected system and keeping hard copies in lock and key. After study completion, data will be archived and retained for maximum years as recommended by Institutional and regulatory requirements.
Statistical Consideration:
The Statistical Package for Social Sciences (SPSS) version 19.0 will be used to analyze data. Quantitative variables will be expressed as mean ± standard deviation and qualitative variables as frequencies (percentages). The efficacy in intervention group on the basis of successful clinical and functional outcome achievement and the safety in intervention group on the basis of reported AEs/SAEs will be assessed by intention to treat analysis (ITT). The p-values for Group comparisons of clinical and functional categorical outcomes will be generated by chi-square test or Fisher Exact value of less than 0.05 will be considered as statistically significant with a confidence interval of 95%.
To patient and doctor satisfaction scores will be analyzed using regression analysis. For Assessment of outcomes at 6 weeks, 3 months and 6 months Investigator will use repeated measure ANOVA and generalized estimating equation (GEE). Multiple regression will be used to assess the association between multiple covariates and numeric outcome.
Device Safety:
No specific harm has been demonstrated by limited use of classic blue tooth technology up to date. Still if any adverse event is encountered like headache due to video based learning, increasing pain and/or numbness at the affected anatomical site, worsening range of motion etc., will be reported at the same time to the Institutional and other regulatory authorities as required and recommended by the Sponsor using telephone and e-mail. SAEs will be reported within 24 hours of knowing the event via telephone and e-mail. The completed forms will be submitted in time as recommended by the Sponsor otherwise within 10 days of knowing the event.
Withdrawals:
If patients would like to withdraw from the study due to any reason, he/she may stop participating in the research at any time without losing any of his/her patient rights. On the other hand, if in view of Principal Investigator, the subject is non-compliant and non-cooperative, he/she has right to withdraw the subject from the research study.
Inclusion Criteria:
Exclusion Criteria:
zehra.abdul@aku.edu+92 21 34864258 ext. 4258
tashfeen.ahmad@aku.edu+92 21 34864742 ext. 4742